Formulary Decisions

Indication

In adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: in patients inadequately controlled on their maximally tolerated dose of metformin alone;in combination with other glucose-lowering medicinal products, including insulin, ...

In adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: in patients inadequately controlled on their maximally tolerated dose of metformin alone;in combination with other glucose-lowering medicinal products, including insulin, in patients inadequately controlled with metformin and these medicinal products; n patients already being treated with the combination of dapagliflozin and metformin as separate tablets. SMC restriction: to use in patients for whom a combination of dapagliflozin and metformin is an appropriate choice of therapy, i.e. - when metformin alone does not provide adequate glycaemic control and a sulphonylurea is inappropriate; - in combination with insulin, when insulin and metformin does not provide adequate control; - in combination with a sulphonylurea, when a sulphonylurea and metformin does not provide adequate control.